London Stock Exchange welcomes Arix Bioscience plc to the Main Market
Arix Bioscience (the "Company") is a global healthcare and life science company, which sources, finances and develops high quality healthcare and life science businesses. The focus is on generating value from the development and commercialisation of innovative technologies and discoveries. The Company has raised £100 million (gross) in its IPO on the Main Market of London Stock Exchange by way of an oversubscribed issue of New Ordinary Shares from a broad range of investors including Woodford Investment Management (acting on behalf of its fund clients) and pharmaceutical companies UCB S.A. and Takeda Pharmaceuticals (working through its ventures group, Takeda Ventures, Inc.). Based on the Offer Price, Arix's total market capitalisation at Admission was approximately £187 million. Arix will trade under the ticker symbol "ARIX".
Headquartered in London and with an office in New York, the Company already has direct holdings in five companies which the Company believes have the potential to provide significant breakthroughs in areas of acute unmet medical need (the "Group Businesses"), and indirect interests in a further 19 businesses through its partnership with BioMotiv and ownership of Arthurian Life Sciences Limited. Arix will use the proceeds of the Offer, together with its existing cash resources, to continue sourcing, financing, developing and, ultimately, commercialising innovative technologies and discoveries.
The Company seeks to accelerate the development of important new medicines from scientific innovation through the support of existing and new Group Businesses, with finance and active support. The funds will also be used to build the Group's infrastructure, including its high quality operating team and its commitments to relationships with research organisations, globally.
Jefferies acted as global coordinator and bookrunner in relation to the offer alongside WG Partners as placing agent and Scott Harris as intermediaries offer agent.
Commenting on the IPO, CEO of Arix Bioscience plc, Joe Anderson, said:
"Following decades of progress in fundamental science, the life science industry is currently going through an incredibly productive phase. Through our network of academic institutions, research accelerators, our own fund management organisation and the team’s extensive links within the industry, Arix Bioscience has established privileged access to some of the world’s most exciting medical innovation. We believe we can build businesses which improve outcomes for patients and unlock value for investors.
"Our team is comprised of industry figures who have proven their ability to identify, build and operate successful life science businesses, and is supported by a very strong Board. The strong level of investor interest in this oversubscribed IPO demonstrates the commitment and enthusiasm for the life science sector and we aim to keep building momentum at Arix and remain at the forefront of innovation whilst delivering value to our shareholders."